Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss

NeuroImage ◽  
2012 ◽  
Vol 59 (4) ◽  
pp. 3339-3346 ◽  
Author(s):  
Esther Aarts ◽  
Rick C. Helmich ◽  
Marcel J.R. Janssen ◽  
Wim J.G. Oyen ◽  
Bastiaan R. Bloem ◽  
...  
2018 ◽  
Vol 304 ◽  
pp. 143-153 ◽  
Author(s):  
Claude Rouillard ◽  
Joanie Baillargeon ◽  
Brigitte Paquet ◽  
Michel St-Hilaire ◽  
Jérôme Maheux ◽  
...  

2001 ◽  
Vol 169 (1) ◽  
pp. 163-181 ◽  
Author(s):  
Manuel Rodrı́guez ◽  
Pedro Barroso-Chinea ◽  
Patricio Abdala ◽  
José Obeso ◽  
Tomás González-Hernández

Endocrinology ◽  
2003 ◽  
Vol 144 (7) ◽  
pp. 2757-2760 ◽  
Author(s):  
Tamas L. Horvath ◽  
Sabrina Diano ◽  
Csaba Leranth ◽  
Luis Miguel Garcia-Segura ◽  
Michael A. Cowley ◽  
...  

Abstract Parkinson’s disease is characterized by dopamine cell loss of the substantia nigra. Parkinson’s disease and the neurotoxin 1-methyl-4-phenyl-1,2,5,6 tetrahydropyridine may destroy dopamine neurons through oxidative stress. Coenzyme Q is a cofactor of mitochondrial uncoupling proteins that enhances state-4 respiration and eliminate superoxides. Here we report that short-term oral administration of coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss after 1-methyl-4-phenyl-1,2,5,6 tetrahydropyridine administration in monkeys.


2016 ◽  
Vol 89 ◽  
pp. 55-64 ◽  
Author(s):  
Ludovico Arcuri ◽  
Riccardo Viaro ◽  
Simone Bido ◽  
Francesco Longo ◽  
Mariangela Calcagno ◽  
...  

2011 ◽  
Vol 100 (1) ◽  
pp. 173-189 ◽  
Author(s):  
Yilong Ma ◽  
Shichun Peng ◽  
Vijay Dhawan ◽  
David Eidelberg

2015 ◽  
Vol 113 (1) ◽  
pp. 200-205 ◽  
Author(s):  
Kenneth T. Kishida ◽  
Ignacio Saez ◽  
Terry Lohrenz ◽  
Mark R. Witcher ◽  
Adrian W. Laxton ◽  
...  

In the mammalian brain, dopamine is a critical neuromodulator whose actions underlie learning, decision-making, and behavioral control. Degeneration of dopamine neurons causes Parkinson’s disease, whereas dysregulation of dopamine signaling is believed to contribute to psychiatric conditions such as schizophrenia, addiction, and depression. Experiments in animal models suggest the hypothesis that dopamine release in human striatum encodes reward prediction errors (RPEs) (the difference between actual and expected outcomes) during ongoing decision-making. Blood oxygen level-dependent (BOLD) imaging experiments in humans support the idea that RPEs are tracked in the striatum; however, BOLD measurements cannot be used to infer the action of any one specific neurotransmitter. We monitored dopamine levels with subsecond temporal resolution in humans (n = 17) with Parkinson’s disease while they executed a sequential decision-making task. Participants placed bets and experienced monetary gains or losses. Dopamine fluctuations in the striatum fail to encode RPEs, as anticipated by a large body of work in model organisms. Instead, subsecond dopamine fluctuations encode an integration of RPEs with counterfactual prediction errors, the latter defined by how much better or worse the experienced outcome could have been. How dopamine fluctuations combine the actual and counterfactual is unknown. One possibility is that this process is the normal behavior of reward processing dopamine neurons, which previously had not been tested by experiments in animal models. Alternatively, this superposition of error terms may result from an additional yet-to-be-identified subclass of dopamine neurons.


Author(s):  
John V. Hindle ◽  
Sion Jones ◽  
Glesni Davies

Parkinson’s disease (PD) is a progressive neurodegenerative condition characterized clinically by fatiguable bradykinesia, rigidity and tremor and pathologically by deposition of Lewy bodies and cell loss in the substantia nigra and other brain regions. Parkinsonism is the term used to describe the clinical features of conditions resembling PD. Their management requires specialist assessment and a multidisciplinary approach. Levodopa remains the mainstay of treatment for PD. Although other treatments are used, older people are more sensitive to their side effects. Non-motor symptoms, particularly neuropsychiatric problems, significantly impact quality of life and need special consideration in older people. Towards the later stage of the disease, management can be complex, and should involve advanced care planning.


2016 ◽  
Vol 15 (1) ◽  
pp. 73-79 ◽  
Author(s):  
Meghan G. Thomas ◽  
Caitlyn Welch ◽  
Leah Stone ◽  
Peter Allan ◽  
Roger A. Barker ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document